Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Carcinoma, Basal Cell 1

Interventions

Nivolumab 3HhAntag691 3Biopsy 3relatlimab 2pembrolizumab 2cemiplimab 2Specimen Handling 2Radiotherapy 2Observation 2Niacinamide 2Magnetic Resonance Spectroscopy 2Ipilimumab 2sonidegib 1prednylidene 1deltacortene 1daromun 1X-Rays 1Watchful Waiting 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1Sirolimus 1Second Harmonic Generation Microscopy 1Prednisone 1Predictive Learning Models 1Practice Guidelines as Topic 1Opdualag 1Interleukin-2 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Basal Cell × daromun × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡